Potassium Hydroxy Citrate Promotes Longevity and Efficacy of Anti-Tumor T cells for Adoptive Cell Therapy (ACT)


Adoptive cell therapy (ACT) using tumor-specific T cells can produce positive clinical responses in some cancer patients. Nevertheless, several obstacles to the successful use of ACT for the treatment of cancer and other conditions remain. For example, one or more of the in vivo persistence, survival, and antitumor activity of tumor-specific T cells can, in some cases, decrease following adoptive transfer. Accordingly, there is a need for methods of obtaining a robust population of tumor-specific T cells for ACT.

Researchers at the National Cancer Institute (NCI) have discovered a novel method to generate long-lived memory tumor-specific T cells with enhanced anti-tumor activity for ACT using potassium hydroxy citrate. Tumor-specific murine T cells grown ex vivo in potassium hydroxy citrate demonstrate enhanced tumor clearance and persistence upon transfer to tumor-bearing mice. Mechanistically, potassium hydroxy citrate treatment leads to reduced glycolysis and cytoplasmic acetyl-CoA levels and activates autophagy in tumor-specific T cells. Furthermore, potassium hydroxy citrate-treated T cells express enhanced levels of markers consistent with long-lived memory anti-tumor T cells. 

The NCI, Surgery Branch, is seeking statements of capability or interest from parties interested in licensing this invention and/or collaborative research to further develop, evaluate, or commercialize potassium hydroxy citrate to enhance the anti-tumor activity of tumor-specific T cells for ACT. 



Potential Commercial Applications: Competitive Advantages:
  • Improved in vivo effector function and longevity of adoptively transferred T cells
 
  • Potassium hydroxy citrate-containing media can be readily incorporated into existing T cell therapy manufacturing processes
  • Potassium hydroxy citrate activates autophagy in tumor-specific T cells which is critical for survival and memory formation 


Development Stage:
Pre-clinical (in vivo)

Related Invention(s):
E-002-2018
E-084-2016


Inventors:

Suman Vadnala (NCI)  ➽ more inventions...

Nicholas Restifo (NCI)  ➽ more inventions...

Rigel Kishton (NCI)  ➽ more inventions...

Robert Eil (NCI)  ➽ more inventions...


Intellectual Property:
Application No. 62/661,941

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-094-2018
Updated: Oct 15, 2018